SXTC (China SXT Pharmaceuticals) ROC %: -591.74% (As of Sep. 2025)


SXTC China SXT Pharmaceuticals Inc SXTC
26 GF Score
Price $2.35
! 5 Warning Signs
View Full Analysis

What is China SXT Pharmaceuticals ROC %?

China SXT Pharmaceuticals SXTC -7.48% 26 ROC % is -591.74% as of Sep. 2025. GuruFocus rates SXTC with a GF Score™ of 26/100. The stock has 5 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. China SXT Pharmaceuticals's annualized return on capital (ROC %) for the quarter that ended in Sep. 2025 was -591.74%.

As of today (2026-06-25), China SXT Pharmaceuticals's WACC % is 19.70%. China SXT Pharmaceuticals's ROC % is -73.36% (calculated using TTM income statement data). China SXT Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.

China SXT Pharmaceuticals  (NAS:SXTC) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, China SXT Pharmaceuticals's WACC % is 19.70%. China SXT Pharmaceuticals's ROC % is -73.36% (calculated using TTM income statement data). China SXT Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

China SXT Pharmaceuticals ROC % Related Terms

China SXT Pharmaceuticals ROC % Historical Data

* Premium members only.

The historical data trend for China SXT Pharmaceuticals's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China SXT Pharmaceuticals ROC % Chart

China SXT Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
ROC %
Get a 7-Day Free Trial Premium Member Only -18.30 -39.55 -40.30 -18.98 -38.46

China SXT Pharmaceuticals Semi-Annual Data
Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -189.52 158.46 -6.08 -25.59 -591.74
SXTC
26GF Score
China SXT Pharmaceuticals Inc SXTC
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China SXT Pharmaceuticals ROC % Calculation

China SXT Pharmaceuticals's annualized Return on Capital (ROC %) for the fiscal year that ended in Mar. 2025 is calculated as:

ROC % (A: Mar. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Mar. 2024 ) + Invested Capital (A: Mar. 2025 ))/ count )
=-2.68 * ( 1 - 0% )/( (12.01 + 1.927)/ 2 )
=-2.68/6.9685
=-38.46 %

where

Invested Capital(A: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=23.127 - 5.786 - ( 12.07 - max(0, 8.902 - 14.233+12.07))
=12.01

Invested Capital(A: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=21.664 - 4.453 - ( 18.099 - max(0, 6.012 - 21.296+18.099))
=1.927

China SXT Pharmaceuticals's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2025 is calculated as:

ROC % (Q: Sep. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2025 ) + Invested Capital (Q: Sep. 2025 ))/ count )
=-12.678 * ( 1 - 0% )/( (1.927 + 2.358)/ 2 )
=-12.678/2.1425
=-591.74 %

where

Invested Capital(Q: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=21.664 - 4.453 - ( 18.099 - max(0, 6.012 - 21.296+18.099))
=1.927

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=26.353 - 3.914 - ( 21.166 - max(0, 5.961 - 26.042+21.166))
=2.358

Note: The Operating Income data used here is two times the semi-annual (Sep. 2025) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -591.74% mean?
China SXT Pharmaceuticals (SXTC) has a ROC % of -591.74% as of Sep. 2025. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on China SXT Pharmaceuticals and its competitors.
Is China SXT Pharmaceuticals' ROC % too high?
China SXT Pharmaceuticals' current ROC % is -591.74%. Overall, China SXT Pharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does China SXT Pharmaceuticals' ROC % compare to YCBD and CVSI?
China SXT Pharmaceuticals' ROC % of -591.74% can be compared against companies in the Drug Manufacturers industry. The industry median ROC % is 4.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Drug Manufacturers company?
The median ROC % among Drug Manufacturers companies is 4.44, based on 985 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on China SXT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median ROC % is 4.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China SXT Pharmaceuticals's current ROC % is -591.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China SXT Pharmaceuticals stock overvalued right now?
China SXT Pharmaceuticals (SXTC) has a current ROC % of -591.74%. The current ROC % is -591.74%. China SXT Pharmaceuticals' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For China SXT Pharmaceuticals (SXTC), the current ROC % is -591.74% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

China SXT Pharmaceuticals Business Description

Address No. 178 Taidong Road North, Jiangsu, Taizhou, CHN, 225300
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
26GF Score

Get the complete analysis for SXTC

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.35
Price